Clarification: Amylin FDA info request story

In a story March 15, The Associated Press reported that Bydureon is the proposed trade name of exenatide, a diabetes treatment being developed by Amylin Pharmaceuticals Inc., Eli Lilly&Co. and Alkermes Inc. The story should have specified that the once-weekly form of the drug, exenatide LAR, would be called Bydureon. A daily version of exenatide already is sold in the U.S. under the brand name Byetta.

SEARCH